A clinical trial led by our center reported a 37% overall response rate to daily oral AKT inhibition using GSK2110183 in combination with six cycles of 3-weekly carboplatin (AUC5) and paclitaxel (175 mg/m2) in clinically platinum-resistant ovarian cancer: a patient group with an expected response rate to carboplatin/taxol of only 10–14% (94). This evidence concerns the gene AKT1 and ovarian carcinoma.